晨光生物
(300138)
| 流通市值：40.90亿 | | | 总市值：48.80亿 |
| 流通股本：4.46亿 | | | 总股本：5.33亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,871,515,007.68 | 5,169,444,187.28 | 3,668,696,988.23 | 1,817,862,277.48 |
| 营业收入 | 6,871,515,007.68 | 5,169,444,187.28 | 3,668,696,988.23 | 1,817,862,277.48 |
| 二、营业总成本 | 6,450,813,191.25 | 4,800,484,167.22 | 3,406,936,968.59 | 1,687,768,846.85 |
| 营业成本 | 6,073,599,318.08 | 4,537,459,857.09 | 3,236,975,859.81 | 1,585,966,370.73 |
| 税金及附加 | 16,771,739.78 | 12,034,033.8 | 8,278,108.49 | 3,743,397.99 |
| 销售费用 | 61,075,598.21 | 45,904,689.02 | 29,581,132.84 | 11,243,195.89 |
| 管理费用 | 154,612,330.46 | 115,681,594.85 | 76,818,840 | 41,455,379.95 |
| 研发费用 | 97,400,025.19 | 61,110,369.6 | 38,399,859.82 | 17,814,917.96 |
| 财务费用 | 47,354,179.53 | 28,293,622.86 | 16,883,167.63 | 27,545,584.33 |
| 其中:利息费用 | 83,507,323.17 | 60,947,433.02 | 42,128,967.66 | 24,134,203.91 |
| 其中:利息收入 | 35,633,978.21 | 26,698,664.08 | 15,308,197.11 | 6,045,022.75 |
| 加:公允价值变动收益 | 5,363,332.98 | -2,650,493.03 | 6,583,420.53 | 5,312,194.04 |
| 加:投资收益 | 68,650,895.5 | 53,586,419.2 | 47,643,119.38 | 10,596,612.31 |
| 资产处置收益 | -632,753 | 189.31 | -1,551.18 | 29,641.48 |
| 资产减值损失(新) | 4,056,267.83 | 12,384,026.19 | 12,907,442.35 | 762,072.74 |
| 信用减值损失(新) | -1,126,405.44 | -334,600.91 | -541,519.32 | 171,453.93 |
| 其他收益 | 51,311,383.13 | 32,879,528.9 | 25,625,090.04 | 7,428,863.74 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 548,324,537.43 | 464,825,089.72 | 353,976,021.44 | 154,394,268.87 |
| 加:营业外收入 | 9,905,518.64 | 8,315,832.46 | 4,072,197.18 | 1,570,461.17 |
| 减:营业外支出 | 2,411,388.15 | 1,991,681.07 | 1,466,069.02 | 410,908.6 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 555,818,667.92 | 471,149,241.11 | 356,582,149.6 | 155,553,821.44 |
| 减:所得税费用 | 61,645,361.16 | 55,038,103.36 | 41,689,712.98 | 15,611,005.5 |
| 六、净利润 | 494,173,306.76 | 416,111,137.75 | 314,892,436.62 | 139,942,815.94 |
| 持续经营净利润 | 494,173,306.76 | 416,111,137.75 | 314,892,436.62 | 139,942,815.94 |
| 归属于母公司股东的净利润 | 479,722,222.22 | 398,355,550.46 | 298,654,394.22 | 135,043,557.83 |
| 少数股东损益 | 14,451,084.54 | 17,755,587.29 | 16,238,042.4 | 4,899,258.11 |
| (一)基本每股收益 | 0.9 | 0.75 | 0.56 | 0.25 |
| (二)稀释每股收益 | 0.9 | 0.75 | 0.56 | 0.25 |
| 八、其他综合收益 | 7,223,216.27 | 13,422,891.22 | 19,050,485.22 | 10,558,683.33 |
| 归属于母公司股东的其他综合收益 | 7,223,216.27 | 13,422,891.22 | 19,050,485.22 | 10,558,683.33 |
| 九、综合收益总额 | 501,396,523.03 | 429,534,028.97 | 333,942,921.84 | 150,501,499.27 |
| 归属于母公司股东的综合收益总额 | 486,945,438.49 | 411,778,441.68 | 317,704,879.44 | 145,602,241.16 |
| 归属于少数股东的综合收益总额 | 14,451,084.54 | 17,755,587.29 | 16,238,042.4 | 4,899,258.11 |
| 公告日期 | 2024-04-18 | 2023-10-24 | 2023-08-14 | 2023-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |